Evidence mapPaperPMID 40724028Full record

ReviewAntibiotics (Basel, Switzerland)2025

The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents.

Francesca Serapide, Salvatore Rotundo, Luca Gallelli, Caterina Palleria, Manuela Colosimo, Sara Palma Gullì, Gianmarco Marcianò, Alessandro Russo

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca SerapideDepartment of Medical and Surgical Sciences, University 'Magna Graecia' of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-5555-3732
Salvatore RotundoInfectious and Tropical Disease Unit, "Renato Dulbecco" Hospital, 88100 Catanzaro, Italy.ORCID 0000-0001-5441-1727
Luca GallelliDepartment of Health Science, University 'Magna Graecia' of Catanzaro, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0003-0858-7902
Caterina PalleriaClinical Pharmacology and Pharmacovigilance Unit, "Renato Dulbecco" University Hospital Viale Europa, 88100 Catanzaro, Italy.
Manuela ColosimoMicrobiology and Virology Unit, "Renato Dulbecco" University Hospital, 88100 Catanzaro, Italy.
Sara Palma GullìInfectious and Tropical Disease Unit, "Renato Dulbecco" Hospital, 88100 Catanzaro, Italy.
Gianmarco MarcianòClinical Pharmacology and Pharmacovigilance Unit, "Renato Dulbecco" University Hospital Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0003-1478-9551
Alessandro RussoDepartment of Medical and Surgical Sciences, University 'Magna Graecia' of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0003-3846-4620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe landscape of antimicrobial therapy is undergoing a profound transformation; the contemporary arsenal of antimicrobials, particularly those with extended half-lives and enhanced tissue penetration, necessitates critically reassessing these traditional paradigms. The growing emphasis on antimicrobial stewardship programs has underscored the importance of optimizing antimicrobial agents to minimize the development and spread of resistance. Shorter treatment durations, when clinically appropriate, represent a key strategy in this endeavor.

methodsThis narrative review provides a comprehensive synthesis of current evidence on the duration of antimicrobial therapy, with a particular focus on the clinical and pharmacological implications of novel agents, including long-acting formulations.

resultsWe critically examine the pharmacokinetic and pharmacodynamic properties of these agents, evaluate the opportunities and limitations associated with treatment shortening strategies, and underscore the pivotal role of antimicrobial stewardship in optimizing therapeutic outcomes within an increasingly complex and evolving landscape.

conclusionsThe future of antimicrobial therapy lies in a personalized approach, where treatment decisions are tailored to the individual patient, but detailed clinical trials are necessary to evaluate these approaches.

Indexed as

antibioticshalf-lifepharmacodynamicpharmacokineticresistance

Identifiers

PMID40724028
PMCPMC12291801

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.